New trial aims to beat cancer fatigue with common drug
NCT ID NCT07543536
First seen Apr 23, 2026 · Last updated Jun 12, 2026 · Updated 11 times
Summary
This study tests whether megestrol acetate, a drug often used for appetite loss, can prevent or reduce severe tiredness in 132 women with advanced breast cancer who are starting a treatment called trastuzumab deruxtecan (T-DXd). Participants will receive either megestrol acetate or a placebo, and researchers will track fatigue levels and quality of life over time. The goal is to help patients feel better during cancer therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun yat-Sen University Cancer Center
Guangzhou, Yuexiu District, 510060, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.